G+T advised Agilex Biolabs on its acquisition by Healius for an enterprise value of $301.3 million.
Agilex is one of Australia’s leading bioanalytical laboratory businesses with 25 years’ experience in performing regulated bioanalysis. Agilex provides a comprehensive suite of bioanalytic services for the end-to-end clinical trial needs of biotech and pharmaceutical companies across all major therapeutic areas, with a particular focus and expertise in oncology.
Corporate Advisory Partner Tim Gordon led the matter for G+T, together with lawyers Matthew Wheatley and Emily Fanning.
Tim said “We’ve seen incredible transactional activity over the last few years in the health space, both with financial sponsors and listed players. The acquisition by Healius is recognition of the wonderful business that Agilex has built in a critical sector, and we were grateful to be involved in this milestone transaction. “
G+T’s Corporate Advisory team has leading experience advising on transactions around critical health assets, including advising Virtus Health on its approaches from CapVest and BGH and advising Avance Clinical on its investment from the Riverside Company in recent months. G+T’s Corporate Advisory team advises on many of Australia’s largest and most innovative transactions across a broad range of industries, including advising Afterpay on its proposed $39 billion acquisition by Square, Inc., KKR on completing the acquisition of a majority interest in Colonial First State and establishing a strategic partnership with Commonwealth Bank of Australia, PowAR consortium on its $3 billion take private of Tilt Renewables and MIRA and Aware Super on the acquisition of Vocus. The team is recognised in the leading legal directories, including being ranked Band 1 for Private Equity and Corporate/M&A by Chambers Asia-Pacific, and was awarded Technology, Media, and Telecom M&A Legal Adviser of the Year and Private Equity Legal Adviser of the Year at the 2021 Mergermarket Australian M&A Awards.